- Home
- EPAM vs RGEN Comparison
EPAM vs RGEN Comparison
Compare EPAM & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | RGEN |
|---|---|---|
| Founded | 1993 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 8.2B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPAM | RGEN |
|---|---|---|
| Price | $204.13 | $157.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $211.54 | $174.90 |
| AVG Volume (30 Days) | ★ 918.5K | 671.3K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.55 | 0.03 |
| Revenue | ★ $5,297,859,000.00 | $707,890,000.00 |
| Revenue This Year | $17.39 | $17.84 |
| Revenue Next Year | $7.03 | $12.57 |
| P/E Ratio | ★ $31.43 | $6,212.76 |
| Revenue Growth | ★ 14.26 | 11.74 |
| 52 Week Low | $138.15 | $102.97 |
| 52 Week High | $269.00 | $182.52 |
Technical Indicators
Market Signals| Indicator | EPAM | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.16 | 47.22 |
| Support Level | $203.10 | $156.01 |
| Resistance Level | $214.43 | $165.02 |
| Average True Range (ATR) | 6.16 | 4.67 |
| MACD | -0.26 | -1.45 |
| Stochastic Oscillator | 66.06 | 7.25 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.